Lorcaserin Hydrochloride Patent Expiration
Lorcaserin Hydrochloride is used for chronic weight management by treating obesity in patients who have achieved a 5% weight loss on a reduced-calorie diet. It was first introduced by Eisai Inc
Lorcaserin Hydrochloride Patents
Given below is the list of patents protecting Lorcaserin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Belviq | US8999970 | Administration of an anti-obesity compound to individuals with renal impairment | Feb 07, 2033 | Eisai Inc |
| Belviq Xr | US8999970 | Administration of an anti-obesity compound to individuals with renal impairment | Feb 07, 2033 | Eisai Inc |
| Belviq | US9169213 | Method of weight management | Dec 06, 2032 | Eisai Inc |
| Belviq Xr | US9169213 | Method of weight management | Dec 06, 2032 | Eisai Inc |
| Belviq | US9770455 | Administration of an anti-obesity compound to individuals with renal impairment | Aug 31, 2031 | Eisai Inc |
| Belviq Xr | US10226471 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | Aug 31, 2031 | Eisai Inc |
| Belviq Xr | US10463676 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | Aug 31, 2031 | Eisai Inc |
| Belviq Xr | US9770455 | Administration of an anti-obesity compound to individuals with renal impairment | Aug 31, 2031 | Eisai Inc |
| Belviq | US8168624 | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride | Apr 18, 2029 | Eisai Inc |
| Belviq Xr | US8168624 | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride | Apr 18, 2029 | Eisai Inc |
| Belviq | US8697686 | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride | Dec 20, 2025 | Eisai Inc |
| Belviq | US8980881 | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride | Dec 20, 2025 | Eisai Inc |
| Belviq Xr | US8697686 | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride | Dec 20, 2025 | Eisai Inc |
| Belviq Xr | US8980881 | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride | Dec 20, 2025 | Eisai Inc |
| Belviq | US8946207 | Processes for preparing 3-benzazepines |
Jun 16, 2024
(Expired) | Eisai Inc |
| Belviq Xr | US8946207 | Processes for preparing 3-benzazepines |
Jun 16, 2024
(Expired) | Eisai Inc |
| Belviq | US7169401 | Topical skin care composition containing refined peanut oil |
Jul 18, 2023
(Expired) | Eisai Inc |
| Belviq | US6953787 | 5HT2C receptor modulators |
Apr 10, 2023
(Expired) | Eisai Inc |
| Belviq | US7514422 | 5HT2c receptor modulators |
Apr 10, 2023
(Expired) | Eisai Inc |
| Belviq | US7977329 | 5HT2C receptor modulators |
Apr 10, 2023
(Expired) | Eisai Inc |
| Belviq | US8207158 | 5HT2c receptor modulators |
Apr 10, 2023
(Expired) | Eisai Inc |
| Belviq | US8273734 | 5HT2C receptor modulators |
Apr 10, 2023
(Expired) | Eisai Inc |
| Belviq | US8367657 | Processes for preparing 3-benzazepines |
Apr 10, 2023
(Expired) | Eisai Inc |
| Belviq | US8546379 | 5HT2C receptor modulators |
Apr 10, 2023
(Expired) | Eisai Inc |
| Belviq | US8575149 | 5HT2C receptor modulators |
Apr 10, 2023
(Expired) | Eisai Inc |
| Belviq Xr | US6953787 | 5HT2C receptor modulators |
Apr 10, 2023
(Expired) | Eisai Inc |
| Belviq Xr | US7514422 | 5HT2c receptor modulators |
Apr 10, 2023
(Expired) | Eisai Inc |
| Belviq Xr | US7977329 | 5HT2C receptor modulators |
Apr 10, 2023
(Expired) | Eisai Inc |
| Belviq Xr | US8207158 | 5HT2c receptor modulators |
Apr 10, 2023
(Expired) | Eisai Inc |
| Belviq Xr | US8273734 | 5HT2C receptor modulators |
Apr 10, 2023
(Expired) | Eisai Inc |
| Belviq Xr | US8367657 | Processes for preparing 3-benzazepines |
Apr 10, 2023
(Expired) | Eisai Inc |
| Belviq Xr | US8546379 | 5HT2C receptor modulators |
Apr 10, 2023
(Expired) | Eisai Inc |
| Belviq Xr | US8575149 | 5HT2C receptor modulators |
Apr 10, 2023
(Expired) | Eisai Inc |
Lorcaserin Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List